Home Information & Technology IT Software Migraine with Brainstem Aura Market

Migraine with Brainstem Aura Market Size, Share & Trends Analysis Report By Diagnosis (Magnetic Resonance Imaging (MRI), Computerized Tomography (CT), Others), By Treatment (Abortive Medication, Preventive Medication), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), By End-User (Hospitals and Clinics, Diagnostic Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Tejas Zamde | Format:

Market Overview

The global migraine with brainstem aura market size was valued at USD 6.77 billion in 2025 and is projected to grow from USD 7.13 billion in 2026 to USD 10.78 billion by 2034, registering a CAGR of 5.31% during the forecast period from 2026 to 2034. North America dominated the migraine with brainstem aura market with a market share of 38% in 2025.

The expansion of the migraine with brainstem aura market is primarily attributable to rising cases of migraine with aura worldwide, ultimately leading to the growing incidence of migraine with brainstem aura. In addition, the surging prevalence of epilepsy, which is a neurological disease worldwide, is further boosting the global migraine with brainstem aura market. Moreover, the technological innovations and developments in the diagnostic field of migraine with brainstem aura and neuroscience are creating market growth opportunities.

A rare subtype of migraine with aura is migraine with brainstem aura, also referred to as "basilar-type migraine" or "basilar migraine." Migraine is a neurological disorder defined by severe, recurrent migraines that may accompany additional symptoms. Migraine with Brainstem Aura is distinguished by the manifestation of aura symptoms originating from the brainstem, the critical region situated at the base of the brain that regulates numerous bodily processes.

Migraine with aura is a distinct subtype of migraine characterized by the presence of visual, sensory, or additional neurological disruptions preceding or concurrent with the convulsion stage. Transient Ischemic Attacks (TIAs) and other neurological disorders can be confounded with migraine with brainstem aura, which is a relatively uncommon condition. Patients who exhibit these symptoms must promptly seek medical evaluation and diagnosis to ascertain the appropriate course of treatment and exclude alternative potential causes.

Migraine with Brainstem Aura Market Size

Download a Free Sample To learn more about this report.

Segmental Analysis

The global migraine with brainstem aura market is bifurcated into diagnosis, treatment, distribution channel, and end-user.

Based on diagnosis, the global migraine with brainstem aura market is bifurcated into magnetic resonance imaging (MRI), computerized tomography (CT), and others.

MRI, or magnetic resonance imaging, is a medical imaging modality to visualize bodily internal structures. This imaging technique is classified as non-invasive and non-ionizing due to its lack of reliance on hazardous radiation sources such as X-rays or CT scans. MRI operates on the fundamental principles of radio waves and magnetism. Imaging soft tissues, including the brain, spinal cord, musculature, and internal organs, is a specific application of MRI. It is frequently employed across multiple medical disciplines, such as oncology, neurology, orthopedics, and cardiology, to diagnose and monitor various injuries and medical conditions. Since its introduction in the 1970s and 1980s, magnetic resonance imaging (MRI) has exhibited multifunctionality. While MRI is mostly used in diagnostic medicine and biomedical research, it can also be used to imagine nonliving entities, such as mummies.

Migraine with Brainstem Aura Market Size By Segments

Request Customizationto receive a tailored report.

Based on treatment, the global migraine with brainstem aura market is segmented into abortive medication and preventive medication.

Preventive medication, alternatively referred to as prophylactic medication or preventative medicine, constitutes a category of medical interventions employed to avert the commencement or advancement of a particular ailment, state, or health concern. Patients who have a prior medical history of or are at an increased risk of developing a specific health condition are frequently prescribed this medication. In addition, preventive medication plays a pivotal role in individual healthcare plans and public health strategies, as it aids in managing chronic conditions, promotes health maintenance, and lessens the societal and individual burden of disease. Healthcare personnel commonly prescribe this medication following an individual's medical history, risk factors, and particular health requirements. The preventive medicine segment is further bifurcated into antidepressants, Botox injections, and others.

Based on distribution channels, the global migraine with brainstem aura market is bifurcated into retail pharmacies, hospital pharmacies, and others.

Hospital pharmacies are an indispensable component in healthcare facilities like hospitals and clinics, where they provide pharmaceutical services to support patient care. The hospitals and healthcare facilities entrust these pharmacies with the acquisition, storage, preparation, distribution, and administration of pharmaceuticals and medications. Hospital pharmacies are responsible for dispensing medications and verifying that patients are administered the appropriate medications, including the correct dosage and instructions. They execute medication orders in close collaboration with healthcare providers. To mitigate the occurrence of medication errors, hospital pharmacies employ safety protocols, including medication reconciliation.

Based on end-users, the global migraine with brainstem aura market is bifurcated into hospitals and clinics, diagnostic centers, and others.

Hospitals and clinics hold a significant share of the migraine with brainstem aura market, as most migraine with brainstem aura treatments are done in hospitals. Moreover, the growing number of hospitals and specialty clinics across developing countries positively impacts the demand for migraine and brainstem aura treatment procedures. As per the April 2020 report of the Center for Disease Dynamics, Economics, and Policy (CCDEP), there were 25,778 public sector hospitals in India. Moreover, efficient reimbursement programs that hospitals in some nations provide to patients, reducing their financial burden from medical expenses, support the expansion of the hospital market. Hence, from the factors above, the hospital segment is estimated to witness a high share over the forecasted period.

Migraine with Brainstem Aura Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America Dominates the Global Market

Based on region, the global migraine with brainstem aura market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America is the most significant global migraine with brainstem aura market shareholder and is expected to expand substantially during the forecast period. North America, specifically the United States and Canada, are renowned for their highly developed healthcare systems and extensive medical knowledge. This entails the provision of services at headache clinics and specialized neurologists who are capable of diagnosing and treating migraines with brainstem aura. Patients suffering from migraine with brainstem aura in North America are provided with an extensive array of treatment alternatives, encompassing both preventive and acute pharmaceuticals, in addition to non-pharmacological approaches. The treatment options for migraine patients, including those with brainstem aura, have been broadened due to the introduction of more recent, targeted migraine medications, such as calcitonin gene-related peptide (CGRP) inhibitors.

In North America, clinical research and pharmaceutical development are concentrated. In this geographical area, research studies and clinical trials on migraine, encompassing migraine with brainstem aura, are carried out. For instance, the American Heart Association, a prominent nonprofit organization promoting cardiovascular and neurological well-being globally, has allocated USD 2.1 million to support seven novel scientific research initiatives. These studies aim to delve further into the intricate relationship between migraine and its potential implications on the susceptibility to stroke and cardiovascular ailments. The findings of these research endeavors enhance comprehension of the ailment and facilitate the creation of novel therapeutic interventions. All these factors boost market growth in the North American region.

North America Migraine with Brainstem Aura Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

The Asia-Pacific migraine with brainstem aura market is primarily boosted by the huge target population base in the region, advancing healthcare infrastructure, and growing awareness about the disease. In addition, the growing incidence of mental and neurological disorders in the region is also responsible for the growth of migraines in the brainstem aura market in the region. For example, according to the Global Burden of Disease study (2016), India is responsible for 15% of the worldwide disease burden associated with mental and neurological disorders (MNDs).

Furthermore, projections indicate that India's MND burden will increase by 23% by 2025. In accordance with a scholarly publication available in the National Library of Medicine (NLM), it has been reported that the estimated number of individuals affected by epilepsy in India amounts to roughly 10 million. This, in turn, drives the regional market expansion. However, socioeconomic factors and cultural perspectives regarding mental health and migraine may influence the quality of care and assistance provided to people with migraine in the Asia-Pacific area, thereby restricting market growth in the region.

List of Key and Emerging Players in Migraine with Brainstem Aura Market

Pfizer, Inc.
AstraZeneca
GlaxoSmithKline Plc
Abbott Laboratories
Merck & Co., Inc.
Eisai Co., Ltd.
Eli Lily and Company
Endo International Plc
Impax Laboratories
Johnson & Johnson

Key Industry Developments

October 2025
Amneal Pharmaceuticals commercially launched Brekiya® in the United States through specialty pharmacy channels, making the first DHE autoinjector broadly available for adults with migraine with or without aura.
May 2025
Amneal Pharmaceuticals received U.S. FDA approval for Brekiya® (dihydroergotamine mesylate) injection, the first ready-to-use DHE autoinjector approved for the acute treatment of migraine with or without aura in adults, expanding acute migraine treatment options.
May 2025
Satsuma Pharmaceuticals (a subsidiary of Shin Nippon Biomedical Laboratories) received U.S. FDA approval for Atzumi™ (dihydroergotamine nasal powder), the first DHE nasal powder approved for the acute treatment of migraine with or without aura in adults.
January 2025
Axsome Therapeutics received U.S. FDA approval for SYMBRAVO® (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults, expanding its prescription migraine treatment portfolio.

Report Scope

Segmentation

By Diagnosis 3
  • Magnetic Resonance Imaging (MRI)
  • Computerized Tomography (CT)
  • Others
By Treatment 2
  • Abortive Medication
  • Preventive Medication
By Distribution Channel 3
  • Retail Pharmacies
  • Hospital Pharmacies
  • Others
By End-User 3
  • Hospitals and Clinics
  • Diagnostic Centers
  • Others

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 8
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Singapore
  • Taiwan
  • Southeast Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Pfizer, Inc. · AstraZeneca · GlaxoSmithKline Plc · Abbott Laboratories · Merck & Co., Inc.
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The migraine with brainstem aura market size is valued at USD 7.13 Billion in 2026 and is projected to reach USD 10.78 Billion by 2034, at a CAGR of 5.31% during the forecast period 2026-2034.

North America dominated the market with a share of 38% in 2025.

The leading companies in this market are Pfizer, Inc., AstraZeneca, GlaxoSmithKline Plc, Abbott Laboratories.

The migraine with brainstem aura market is projected to grow at a CAGR of 5.31% during the forecast period of 2026 2034.
About the Author
Tejas Zamde
Tejas Zamde
Research Analyst

Tejas Zamde is a market research professional with over two years of experience in the technology, semiconductor, electronics, and automotive sectors. He specializes in market assessment, competitive intelligence, industry analysis, market sizing, demand analysis, and strategic research.

His experience includes analyzing technology trends, market dynamics, regulatory developments, supply-demand patterns, value chains, and competitive landscapes across global and regional markets. He has supported clients with opportunity assessment, customer segmentation, competitive benchmarking, and growth strategy development.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: